Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2006; 12(6): 945-950
Published online Feb 14, 2006. doi: 10.3748/wjg.v12.i6.945
Published online Feb 14, 2006. doi: 10.3748/wjg.v12.i6.945
Table 4 Incidence of selected adverse events (>10% frequency)
| Adverse event | RegimenA(CIFN+zinc) | Regimen B(CIFN) |
| n | 41 | 42 |
| Fever | 41 (100%) | 42 (100%) |
| Headache | 17 (41.5%) | 16 (38.1%) |
| Malaise | 15 (36.6%) | 12 (28.6%) |
| Anorexia | 14 (34.1%) | 19 (45.2%) |
| Arthralgia | 14 (34.1%) | 13 (31.0%) |
| Insomnia | 11 (26.8%) | 11 (26.2%) |
| Stomach discomfort | 7 (17.1%) | 5 (11.9%) |
| Alopecia | 6 (14.6%) | 6 (14.3%) |
| depression | 6 (14.6%) | 5 (11.9%) |
| Nausea | 6 (14.6%) | 5 (11.9%) |
| Myalgia | 5 (12.2%) | 6 ( 14.3%) |
| Rash | 5 (12.2%) | 4 (9.5%) |
- Citation: Suzuki H, Sato K, Takagi H, Kanda D, Sohara N, Kakizaki S, Nakajima H, Otsuka T, Nagamine T, Mori M. Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2. World J Gastroenterol 2006; 12(6): 945-950
- URL: https://www.wjgnet.com/1007-9327/full/v12/i6/945.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i6.945